Track Ngm Biopharmaceuticals's current cash ($59M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Ngm Biopharmaceuticals (NGM) currently reports a current cash of $59M as of December 2023. That compares with $270M in the prior-year period — down 78.3% year over year. Use the charts on this page to explore Ngm Biopharmaceuticals's current cash history and peer comparisons.
Ngm Biopharmaceuticals's current cash decreased from $270M to $59M — a 78.3% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Ngm Biopharmaceuticals reported $59M in current cash as of December 2023. That compares with $270M in the prior-year period — down 78.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current current cash of $59M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ngm Biopharmaceuticals, and consider following NGM for alerts when major investors trade the stock.
Ngm Biopharmaceuticals is classified in the Healthcare sector. On current cash, it currently shows $59M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NGM with unrelated industries.